key: cord-0821087-a54uc7mp
authors: Alkodaymi, Mohamad Salim; Omrani, Osama Ali; Fawzy, Nader A.; Shaar, Bader Abou; Almamlouk, Raghed; Riaz, Muhammad; Obeidat, Mustafa; Obeidat, Yasin; Gerberi, Dana; Taha, Rand M.; Kashour, Zakaria; Kashour, Tarek; Berbari, Elie F.; Alkattan, Khaled; Tleyjeh, Imad M.
title: Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis
date: 2022-02-03
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.01.014
sha: fee91573b7346f80a35d5ebe16dbd549267bcecf
doc_id: 821087
cord_uid: a54uc7mp

BACKGROUND: Post-acute COVID-19 Syndrome is now recognized as a complex systemic disease that is associated with substantial morbidity. OBJECTIVES: To estimate the prevalence of persistent symptoms and signs at least 12 weeks after acute COVID-19 at different follow-up periods. DATA SOURCES: Searches were conducted up to October 2021 in Ovid Embase, Ovid Medline, and PubMed. STUDY ELIGIBILITY CRITERIA: Articles in English that reported the prevalence of persistent symptoms among individuals with confirmed SARS-CoV-2 infection and included at least 50 patients with a follow-up of at least 12 weeks after acute illness. METHODS: Random-effect meta-analysis was performed to produce pooled prevalence for each symptom at 4 different follow-up time intervals. Between-studies heterogeneity was evaluated using the I(2) statistic and was explored via meta-regression, considering several a priori study level variables. Risk of bias was assessed using the Joanna Briggs Institute (JBI) tool and the Newcastle-Ottawa Scale for prevalence studies and comparative studies, respectively. RESULTS: After screening 3209 studies, a total of 63 studies were eligible, with a total COVID-19 population of 257,348. The most commonly reported symptoms were fatigue, dyspnea, sleep disorder and concentration difficulty (32%, 25%, 24%, and 22% respectively at 3-<6 months follow-up), effort intolerance, fatigue, sleep disorder and dyspnea (45%, 36%, 29% and 25% respectively at 6-<9 months follow-up), fatigue (37%) and dyspnea (21%) at 9-<12 months and fatigue, dyspnea, sleep disorder, myalgia (41%, 31%, 30%, and 22% respectively at >12 months follow-up). There was substantial between-studies heterogeneity for all reported symptoms prevalence. Meta-regressions identified statistically significant effect modifiers: world region, male gender, diabetes mellitus, disease severity and overall study quality score. Five of six studies including a comparator group consisting of COVID-19 negative cases observed significant adjusted associations between COVID-19 and several long-term symptoms. CONCLUSIONS: This systematic review found that a large proportion of patients experience PACS 3 to 12 months after recovery from the acute phase of COVD-19. However, available studies of PACS are highly heterogeneous. Future studies need to have appropriate comparator groups, standardized symptoms definitions and measurements and longer follow-up.

A significant number of patients who have recovered from acute COVID-19 infection are reporting 82 lasting symptoms resulting in impairment of everyday activities beyond the initial acute period. These 83 post COVID-19 patients suffer from a phenomenon known as "long" or "chronic" COVID-19 or more 84 recently, Post-Acute Sequelae of COVID-19 or Post-Acute COVID-19 syndrome (PACS) (1,2). 85

The terms "long COVID-19" and "post-acute COVID-19 syndrome (PACS)" lack a unified definition. The 87 definition endorsed by the National Institute for Health and Care Excellence (NICE) and the World Health 88

Organization (WHO) as a set of "signs and symptoms that emerge during or after an infection consistent 89

with COVID-19, persist for more than 12 weeks, and are not explained by an alternative diagnosis" (3, 4) . 90

Many experts including the NICE panel also agree to subdivide into two categories: 1-post-COVID-19 91 subacute phase of ongoing symptoms that last 4-12 weeks after the onset of illness, and 2-chronic 92 phase or long COVID-19, defined as symptoms and abnormalities that last more than 12 weeks after the 93 onset of illness and are not explained by an alternative diagnosis (2, 4) . Therefore, we sought to perform a systematic review and meta-analysis of available literature to 102

We subsequently identified a subgroup of these eligible studies that included studies with a comparator 125 group consisting of non-COVID cases. 126

Six reviewers (O.O., M.S.A., M.O., N.A.F., R.A., B.A.S.) examined the titles and abstracts of articles in 128 pairs, using the above pre-defined selection criteria. This was followed by a full text review of each 129 article to confirm meeting the eligibility criteria. Disagreements regarding inclusion of a full-text article 130

were discussed and agreed with the senior reviewer (IT). 131

Data were extracted simultaneously by six reviewers in duplicates (OO, NAF, BAS, RA, MSA, MO) into a 133 pre-specified data collection form, with any discrepancies resolved in consultation with the senior 134 reviewer (IMT). Data were collected across the following domains: study characteristics, follow-up 135 method, baseline demographics and symptom prevalence. Full details of the data collation variables can 136 be found in the supplementary material (Supplement 2). 137

The reviewers independently assessed the risk of bias for each study using the Joanna Briggs Institute 139 (JBI) critical appraisal tool for prevalence studies. JBI critical appraisal checklist for studies reporting 140 prevalence consists of nine questions: (1) Sample frame suitability,(2) Sampling method appropriateness 141

(3) Sample size adequacy,(4) Proper description of study subjects and setting, (5) Sufficient coverage of 142 the identified sample (6) Usage of valid methods for identification of the condition, (7) Standard and 143 reliable way of measurement of the condition for all participants, (8) Appropriate statistical analysis and 144 (9) Adequate response rate (9). Each study was assessed across each of these questions and determined 145 as either 'Yes ', 'No' or 'Unclear' . Studies were assigned an overall score, reflecting the number of 146 questions with a 'Yes' response. 147 J o u r n a l P r e -p r o o f Studies with a comparator group consisting of non-COVID cases were assessed using the Newcastle-148

Ottawa Scale (NOS) (10).The NOS rates observational studies based on 3 parameters: selection, 149 comparability between exposed and unexposed groups, and exposure and outcome assessment. These 150 3 domains can have a maximum score of 4, 2, and 3 stars, respectively. Studies with <5 stars are 151 considered low quality, 5-7 stars moderate quality, and >7 stars high quality. 152

Our outcome of interest was prevalence of symptoms at follow-up across four different follow up 154 intervals: 3-<6 months, 6-<9 months, 9-<12 months and ≥12 months. Due to varying definitions of "day 155 0" to follow up across the literature, we accepted definitions of "day 0" that include COVID-19 symptom 156 onset, COVID-19 diagnosis or hospital discharge after acute illness. We further categorized studies 157 according to the severity of COVID-19, which was defined in this context as patients' setting during 158 acute illness: ranging from outpatient (OP), general inpatient wards (IP) or intensive care unit (ICU) 159 settings. Where symptoms prevalence at follow-up was not reported separately based on COVID-19 160 severity, studies were described as "mixed", for example "mixed IP/ICU". 161

The range of persistent COVID-19 symptoms reported to date was then identified and categorized. 162

Given the exchangeable terminology to refer to symptoms across studies, the following terms were 163 grouped: "sleep disturbance" to refer to insomnia, daytime sleepiness, sleep difficulties, and/or sleep 164 disorders, "concentration difficulties" to refer to confusion, change in level of consciousness and/or 165 concentration, "cognitive impairment" to refer to cognitive dysfunction, brain fog, and/or cognition 166 difficulties, "loss of taste" to refer to taste dysfunction, alteration of taste, dysgeusia, and parageusia, 167 "loss of smell" to refer to smell dysfunction, alteration of smell, anosmia, hyposmia, smell blindness, and 168 olfactory disorders. Signs and symptoms were divided into 7 main systems: mental health, respiratory 169 J o u r n a l P r e -p r o o f system, cardiovascular system, musculoskeletal system, nervous system, gastrointestinal system and 170 other. 171

The total cohort number and the number of patients with different symptoms or complaints were 173 extracted from each study at different follow up times into 4 intervals: 3-<6 months, 6-<9 months, 9-<12 174 months and ≥12 months. We performed separate meta-analyses for the aforementioned follow up 175 intervals where ≥3 studies reported symptom prevalence at that follow up interval. The arcsine 176 transformation was used to obtain a pooled estimate of the prevalence of each symptom. As 177 conventional meta-analysis models assume normally distributed data, the arcsine-based 178

transformations are applied to the proportion data to yield better approximations to the normal 179 distribution and they have the important advantage of stabilizing variances (11,12). We used 180

DerSimonian and Laird random effect model with inverse variance method to pool prevalence (13). We 181 performed subgroup meta-analyses by severity of acute COVID-19 in the included studies, thereby 182 allowing a visual display of heterogeneity due the differences in the severity of illness in reporting 183 studies. We evaluated between-studies heterogeneity using the I 2 statistic, which estimates the 184 variability percentage in effect estimates that is due to heterogeneity rather than to chance (14). Two-185 tailed p<0.05 were considered statistically significant. 186

We performed meta-regression to explore between studies heterogeneity. We considered several a 187 priori chosen study level variables based on clinical plausibility (Supplement 3 

Of the 3209 abstracts screened, 152 full-text articles were reviewed with 63 included in the final analysis 199 

Meta-analysis highlighted the substantial heterogeneity between symptom prevalence's reported across 212 studies, with I 2 statistics ranging from 75.4% (difficulty concentrating at 3-<6 months follow up) to 99.4% 213 (fatigue at 9-<12 months follow up), with the vast majority of symptoms across all follow up intervals 214 producing an I 2 ≥ 90%. The most commonly reported symptoms between 3-<6 months are fatigue (32%, 215 95% CI = 22-44%, number of studies = 25, sample size = 7268) followed by dyspnea (25%, 95% CI = 17-216 34%, number of studies = 28, sample size = 8132), sleep disorder (24%, 95% CI = 8-44%, number of 217 studies = 8, sample size = 4369) and concentration difficulty (22%, 95% CI = 15-31%, number of studies = 218 5, sample size, = 466). Between 6-<9 months, the most common symptoms reported were effort 219 intolerance (45%, 95% CI -25-67%, number of studies = 5, sample size = 850), fatigue (36%, 95% CI = 27-220 46%, number of studies = 19, sample size 8191), sleep disorder (29%, 95% CI 15-45%, number of studies 221 = 12, sample size = 242000), and dyspnea (25%, 95% CI = 20-30%, number of studies = 13, 4384). In the 222 9-<12 months period, the meta-analysis included 9 symptoms with the highest prevalence reported for 223 fatigue (37%, 95% CI = 16-62%, number of studies = 5, sample size = 3758) and dyspnea (21%, 95% CI = 224 14-28%, number of studies = 5, sample size = 3758), with loss of taste being the least reported (6%, 95% 225 CI 1-13%, number of studies = 3, sample size = 1742). Similarly, fatigue was the most reported symptom 226 (41%, 95% CI 30-53%, number of studies = 4, sample size = 1246) in the >12 months period. It is 227 noteworthy that fatigue, dyspnea, myalgia, and sleep disorder were most reported in the >12 months 228 interval; while cough, headache, loss of taste and loss of smell were most common at 6-<9 months 229 ( Figure 2 , Panels A-B, Supplement 6, Panels C-D). 230

Due to a limited number of studies reporting symptom prevalence at 9-<12 months or ≥12 months, 232 meta-regression was performed for symptom prevalence at 3-<6 months and 6-<9 months (Supplement 233 6). Observed statistically significant effect modifiers included: world region where the study was 234 conducted, percentage of study participants who were men, and those who had DM, disease severity 235 category as defined earlier and the overall study quality score. 236

Studies reporting results from Asian populations reported a lower prevalence of fatigue, dyspnea, loss of 237 smell and loss of taste at 3-6 month follow up and a lower prevalence of fatigue at 6-9 month follow up. 238 J o u r n a l P r e -p r o o f A higher proportion of men was found to be associated with a lower prevalence of cough and loss of 239 smell at 6-9 months follow up, whilst a higher proportion of diabetes mellitus as a comorbidity was 240 associated with a lower prevalence of loss of smell and taste at 3-6 and 6-9 month follow up. Studies 241 investigating patients in ICU were associated with a higher prevalence of dyspnea compared to studies 242 investigating an OP population at 3-6 month and 6-9 month follow up intervals. Higher study quality was 243 found to be associated with lower prevalence of dyspnea at 3-6 months and cough at 6-9 months follow 244 up. 245

A total of 6 studies reporting symptoms prevalence included a comparator group consisting of COVID-19 247 negative cases, with a summary of their findings presented in Table 2 (17, 24, 26, 37, 59, 62) . Of these, 2 248 studies compared long term symptom prevalence of COVID-19 cases to either influenza, pneumonia or 249 other respiratory tract infection cases (17, 26) . Overall, all but one study reported higher prevalence of 250 symptoms or adverse event in cases following COVID-19 compared to respective comparator groups, 251 with one negative study specifically assessing olfactory and gustatory dysfunction at 6 months (37). Two 252 out of 6 studies were rigorously designed. One study observed that COVID-19 cases had significantly 253 higher hazard of mood disorder, anxiety and insomnia when compared to matched cohorts with 254 influenza or respiratory tract infection (26). Another study observed that COVID-19 cases have 255 significantly higher prevalence of symptoms at 6 and 9 months follow-up when compared to community 256 controls, including fatigue, sleep difficulties, hair loss, smell disorder, taste disorder, palpitations, chest 257 pain and headaches (45). 258

Studies without comparator groups 260

The studies were generally assessed to have good quality with a mean average critical appraisal score 261 across all studies of 7.97/9. The question that affected the scores the most was "Was the sample size 262 adequate?", with few studies demonstrating appropriate sample size calculations nor representing a 263 significantly large enough sample to provide high external validity (Table S1) . 264

Study quality was assessed via the NOS as moderate to high, ranging from 5 to 9 (maximum 9), with a 266 number of studies using an non-representative sample of healthcare workers (37,59), or having 267 comparability concerns by not adequately matching cases with the comparator group (17,37,59,62) 268 (Table S2) . 269

In this systematic review and meta-analysis of 63 studies with a total of 257,348 COVID-19 patients from 273 different world regions, we observed that patients report several clinically significant symptoms across 274 many organs systems 3 months post-acute COVID-19. In addition, we observed that the high between-275 studies heterogeneity of reported symptoms prevalence could at least be partially explained by clinically 276 plausible effect modifiers such as acute COVID-19 severity, and certain patients' demographics and 277 comorbidities (26, 45, 80, 81) . 278

Our findings lend more support to the initiatives of several countries and organizations that have started 279 to fund more research and disseminate guidelines to better understand, diagnose and treat PACS 280 Nevertheless, the mechanisms that explain these chronic symptoms after COVID-19 are not yet fully 295

understood. In addition to the direct effects of SARS-CoV-2, the immune response to the virus is 296 believed to be partly responsible for the appearance of these lasting symptoms, possibly through 297 facilitating an ongoing hyperinflammatory process (88). Several hypotheses have been proposed to 298 explain the long-term outcomes of COVID-19 infection: a) Sequalae of COVID-19 organ involvement 299 during acute infection, b) COVID-19 patients with chronic symptoms may harbor the virus in several 300 potential tissue reservoirs across the body, which may not be identified by nasopharyngeal swabs, c) 301 cross reactivity of SARS-CoV-2-specific antibodies with host proteins resulting in autoimmunity, d) 302 delayed viral clearance due to immune exhaustion resulting in chronic inflammation and impaired tissue 303

repair, e) mitochondrial dysfunction and impaired immunometabolism, and f) alterations in microbiome 304 leading to long-term health consequences of . Our systematic review provides a rigorous and unique update of previous attempts by other 308

investigators. First, a number of previous reviews either did not assess the included studies for risk of 309 bias or utilized an inappropriate assessment tool, such as the Newcastle-Ottawa Scale for non-310 comparative studies. We observed that the quality of included studies to be a significant contributor to 311 heterogeneity of reported symptoms prevalence, with lower quality studies reporting higher prevalence importantly, we present the first attempt to identify and assess studies including an appropriate non-320 COVID group to provide additional evidence of the association between COVID-19 and the high 321 prevalence of symptoms at follow-up. 322

Although our review included the most recent eligible studies with the largest sample size, there is a 323 degree of consistency between the findings of symptoms prevalence between our meta-analyses and 324 others. We report a prevalence of fatigue of 32%, 36%, 47% and 41% across follow up periods from 3 to 325 6 months, 6 to 9 months, 9 to 12 months and greater than 12 months respectively, which is comparable 326 to the findings of Michelen et al. (30.1%) and Iqbal et al. (37%) . This similarity is also the case for 327 dyspnea, with previous meta-analysis reporting estimates of prevalence between 25 and 35%, as well as 328 myalgia and hair loss. 329

Our study is the largest and most comprehensive systematic review of persistent symptoms after acute 332 COVID-19 to date. However, it has a number of limitations inherent to the included studies and studies 333 design. As noted by previous systematic reviews on this topic, studies included in our review lacked 334 uniform symptom terminology, standardized recording methods, and grouping of multiple symptoms 335 under umbrella terms. This limited our ability to compare prevalence and frequency of these symptoms 336 across the studies. Severity of illness was not described in numerous studies, with results presented for 337 whole cohorts and not presented as sub-groups. Thus, grouping all symptoms of various disease severity 338 yield inaccurate estimates of symptoms frequencies. The high observed statistical heterogeneity as 339 measured by I 2 limit the interpretation of the pooled frequencies, although our extensive meta-340 regression illuminates significant contributors to this heterogeneity; namely severity as defined by 341 highest level of medical care, geographic location, prevalence of diabetes and method of assessing 342 symptom at follow-up (98). Questionnaire. 9/9 COVID-19 positive participants were significantly more likely to report a worsening of health compared to one year prior to follow-up when compared to COVID-19 negative participants.*** *Cardiovascular disease, chronic respiratory disease, chronic kidney disease, hypertension, and diabetes. **obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance use disorder, ischaemic heart disease and other forms of heart disease, socioeconomic deprivation, cancer, haematological cancer, chronic liver disease, stroke, dementia, organ transplant, rheumatoid arthritis, lupus, psoriasis, and disorders involving an immune mechanism. ***Multivariate regression model including age, sex, chronic diseases, smoking, health professional occupation, income level, fitness and time from COVID-19 testing to follow-up. † Study design was derived from manuscript method section and not author description. J o u r n a l P r e -p r o o f

Prevalence and 603 predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 604 4 months median follow-up. PloS one

Long COVID risk -a signal to 606 address sex hormones and women's health. The Lancet regional health Europe

Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-610 19. Annals of internal medicine

In the wake of the 612 pandemic Preparing for Long COVID. World Health Organization

Managing chronic disease in hospitalized patients. JAMA internal 615 medicine

Fear and agony of the pandemic leading to 617 stress and mental illness: An emerging crisis in the novel coronavirus (COVID-19) outbreak. 618 Psychiatry research

High-dimensional characterization of post-acute sequelae of COVID-19. 620

Risk of clinical 622 sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. The Journal 626 of infection

Organ-specific manifestations of COVID-19 infection. Clinical and experimental medicine

Comorbidities and multi-organ injuries in the 631 treatment of COVID-19

Unraveling the Mystery 633

Surrounding Post-Acute Sequelae of COVID-19. Frontiers in immunology

More Than 100 Persistent Symptoms of SARS-CoV-2 (Long 635 COVID): A Scoping Review

Short-term and Long-term 637 Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review

Assessment of the Frequency and Variety of Persistent 640 Symptoms Among Patients With COVID-19: A Systematic Review

More 643 than 50 long-term effects of COVID-19: a systematic review and meta-analysis

Characterising long 646 COVID: a living systematic review

Characteristics and predictors of 648 acute and chronic post-COVID syndrome: A systematic review and meta-analysis

Limitations of Meta-analyses of Studies With High Heterogeneity

Causation or confounding: why controls are critical for 653 characterizing long COVID